{"nctId":"NCT01368081","briefTitle":"Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-05"},"conditions":["Diabetes Mellitus, Type 2"],"count":1162,"armGroups":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL","interventionNames":["Drug: BI 10773","Drug: Placebo (high dose)"]},{"label":"BI 10773 high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo (low dose)","Drug: BI 10773"]},{"label":"Metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"Placebo (low dose)","otherNames":[]},{"name":"BI 10773","otherNames":[]},{"name":"Placebo (high dose)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* .Diagnosis of type 2 diabetes mellitus prior to informed consent\n* Male and female patients, on diet and exercise regimen, who are pre-treated with one of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide, Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or thiazolidinedione\n* glycosylated haemoglobin (HbA1c) at Visit 1: \\>=7.0 to =\\<10.0% (national glycohemoglobin standardization program)\n\nExclusion criteria:\n\n* Uncontrolled hyperglycaemia with a glucose level \\>240 mg/dL (\\>13.3 mmol/L)\n* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent\n* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in HbA1c","description":"Change from baseline in HbA1c after 52 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"0.05"},{"groupId":"OG001","value":"-0.96","spread":"0.05"},{"groupId":"OG002","value":"-0.97","spread":"0.08"},{"groupId":"OG003","value":"-0.81","spread":"0.06"},{"groupId":"OG004","value":"-0.98","spread":"0.06"},{"groupId":"OG005","value":"-0.90","spread":"0.05"},{"groupId":"OG006","value":"-0.96","spread":"0.05"},{"groupId":"OG007","value":"-0.87","spread":"0.06"},{"groupId":"OG008","value":"-0.77","spread":"0.06"},{"groupId":"OG009","value":"-1.00","spread":"0.06"},{"groupId":"OG010","value":"-0.83","spread":"0.06"},{"groupId":"OG011","value":"-0.98","spread":"0.08"},{"groupId":"OG012","value":"-0.98","spread":"0.08"}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Drug Related Adverse Events","description":"Number of Patients With Drug Related Adverse Events after the first drug intake until 7 days after the last treatment administration, up to 383 days","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"9","spread":null},{"groupId":"OG005","value":"20","spread":null},{"groupId":"OG006","value":"19","spread":null},{"groupId":"OG007","value":"7","spread":null},{"groupId":"OG008","value":"5","spread":null},{"groupId":"OG009","value":"9","spread":null},{"groupId":"OG010","value":"18","spread":null},{"groupId":"OG011","value":"9","spread":null},{"groupId":"OG012","value":"9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Confirmed Hypoglycaemic Adverse Events","description":"Number of patients with confirmed hypoglycaemic adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"2","spread":null},{"groupId":"OG006","value":"1","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"0","spread":null},{"groupId":"OG010","value":"1","spread":null},{"groupId":"OG011","value":"0","spread":null},{"groupId":"OG012","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":136},"commonTop":["Nasopharyngitis","Constipation","Fall","Pollakiuria","Back pain"]}}}